Home Stock

Stock Research: SK Biopharmaceuticals

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

SK Biopharmaceuticals

KSC:326030 KR7326030004
28
  • Value
    4
  • Growth
    97
  • Safety
    Safety
    70
  • Combined
    52
  • Sentiment
    26
  • 360° View
    360° View
    28
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

SK Biopharmaceuticals Co Ltd is a Korea-based pharmaceutical company focused on the development and manufacture of drugs. The company operates in the pharmaceutical industry, developing and producing epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, bipolar disorder drugs, and new drug development. The company is based in Korea. In the last fiscal year, the company had a market cap of $5509 millions, profits of $342 millions, and revenue of $371 millions.

more

ANALYSIS: With an Obermatt 360° View of 28 (better than 28% compared with alternatives), overall professional sentiment and financial characteristics for the stock SK Biopharmaceuticals are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for SK Biopharmaceuticals. The consolidated Growth Rank has a good rank of 97, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 97% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 70 which means that the company has a financing structure that is safer than 70% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 4 which means that the share price of SK Biopharmaceuticals is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 96% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 26, which means that professional investors are more pessimistic about the stock than for 74% of alternative investment opportunities. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Growth
Country South Korea
Industry Pharmaceuticals
Size Medium
Website skbp.com
Index
KOSPI
SK Biopharmaceuticals stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 9-Apr-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
4 1 1 1
Growth
97 82 100 93
Safety
Safety
70 4 6 22
Sentiment
26 88 59 52
360° View
360° View
28 35 27 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
48 60 63 59
Opinions Change
50 50 55 50
Pro Holdings
n/a 78 30 22
Market Pulse
21 82 84 70
Sentiment
26 88 59 52
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
4 1 1 1
Growth
97 82 100 93
Safety Safety
70 4 6 22
Combined
52 7 16 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
14 5 1 3
Price vs. Earnings (P/E)
41 7 1 1
Price vs. Book (P/B)
8 1 1 3
Dividend Yield
1 1 1 1
Value
4 1 1 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
93 98 98 81
Profit Growth
95 6 81 88
Capital Growth
88 60 73 91
Stock Returns
33 88 85 9
Growth
97 82 100 93
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
87 19 19 70
Refinancing
10 6 15 11
Liquidity
80 10 6 1
Safety Safety
70 4 6 22

Similar Stocks

Discover high‑ranked alternatives to SK Biopharmaceuticals and broaden your portfolio horizons.

Kinden

TYO:1944
Country: Japan
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

Shionogi

TYO:4507
Country: Japan
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Sinopharm

HKG:1099
Country: China
Industry: Health Care Distributors
Size: X-Large
Full Stock Analysis

Youngone

KSC:111770
Country: South Korea
Industry: Apparel, Accessories, Luxury
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews